GSK malaria vaccine trial halted in Gabon
This article was originally published in Scrip
Gabon has decided to put on hold the start date of a Phase III trial of GlaxoSmithKline's malaria vaccine (RTS,S, AS01/AS02), the most advanced vaccine for the condition to date, which was expected to begin this week in children under two years of age. A roll-out of the trial across seven African countries at 11 sites is expected from mid-April.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.